Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
The Journal of Antimicrobial Chemotherapy
|
December 19, 2023
7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms
Susanne Paukner, Rodrigo E Mendes, S J Ryan Arends, et al.
Pharmacotherapy
|
April 2, 2021
Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired renal function and those requiring hemodialysis
Wolfgang W Wicha, Thomas C Marbury, James A Dowell, et al.
Pharmacotherapy
|
April 3, 2021
Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired-hepatic function
Wolfgang W Wicha, Thomas C Marbury, James A Dowell, et al.
Clinical Therapeutics
|
January 9, 2024
Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis
Gregory S Sawicki, Wolfgang W Wicha, Tara S Hiley, et al.
Future Microbiology
|
March 14, 2022
A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria
Susanne Paukner, Gregory J Moran, Christian Sandrock, et al.
International Journal of Molecular Sciences
|
May 25, 2024
In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice
Susanne Paukner, Sandra Kimber, Charlotte Cumper, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 7, 2014
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials
Stuart Johnson, Thomas J Louie, Dale N Gerding, et al.
Frontiers in Pharmacology
|
December 1, 2022
Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating <i>Neisseria gonorrhoeae</i> infections
Susanne Jacobsson, Daniel Golparian, Joakim Oxelbark, et al.
The Journal of Antimicrobial Chemotherapy
|
April 6, 2019
Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia
Sujata M Bhavnani, Li Zhang, Jeffrey P Hammel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 6, 2019
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M File, Lisa Goldberg, Anita Das, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
The Journal of Antimicrobial Chemotherapy
|
December 19, 2023
7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms
Susanne Paukner, Rodrigo E Mendes, S J Ryan Arends, et al.
Pharmacotherapy
|
April 2, 2021
Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired renal function and those requiring hemodialysis
Wolfgang W Wicha, Thomas C Marbury, James A Dowell, et al.
Pharmacotherapy
|
April 3, 2021
Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired-hepatic function
Wolfgang W Wicha, Thomas C Marbury, James A Dowell, et al.
Clinical Therapeutics
|
January 9, 2024
Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis
Gregory S Sawicki, Wolfgang W Wicha, Tara S Hiley, et al.
Future Microbiology
|
March 14, 2022
A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria
Susanne Paukner, Gregory J Moran, Christian Sandrock, et al.
International Journal of Molecular Sciences
|
May 25, 2024
In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice
Susanne Paukner, Sandra Kimber, Charlotte Cumper, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 7, 2014
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials
Stuart Johnson, Thomas J Louie, Dale N Gerding, et al.
Frontiers in Pharmacology
|
December 1, 2022
Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating <i>Neisseria gonorrhoeae</i> infections
Susanne Jacobsson, Daniel Golparian, Joakim Oxelbark, et al.
The Journal of Antimicrobial Chemotherapy
|
April 6, 2019
Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia
Sujata M Bhavnani, Li Zhang, Jeffrey P Hammel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 6, 2019
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M File, Lisa Goldberg, Anita Das, et al.
Page
of 3